X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Investment volume in life science capital markets is poised to log its best year ever, with first-half 2021 numbers hitting north of $9 billion and aided by Blackstone’s recent $3.45 billion acquisition of Brookfield’s Cambridge portfolio. 

New research from Newmark reveals that the sector has benefited from investors looking to diversify and adjust portfolio risk in the wake of COVID-19. Nationally, pricing remains above average, and June numbers show that pricing surpassed $500 per square foot. Newmark predicts that groups like Alexandria, Blackstone/BioMed Realty, Boston Properties and IQHQ will continue to drive capital markets activity for the rest of this year.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

 

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt
Live Chat

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.